S&P 500   4,544.90
DOW   35,677.02
QQQ   374.10
pixel
S&P 500   4,544.90
DOW   35,677.02
QQQ   374.10
pixel
S&P 500   4,544.90
DOW   35,677.02
QQQ   374.10
pixel
S&P 500   4,544.90
DOW   35,677.02
QQQ   374.10
pixel
ASX:FTT

Factor Therapeutics Stock Forecast, Price & News

Add
Compare
Today's Range N/A
50-Day Range N/A
52-Week Range N/A
Volume425,600 shs
Average VolumeN/A
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
BetaN/A

Receive FTT News and Ratings via Email

Sign-up to receive the latest news and ratings for Factor Therapeutics and its competitors with MarketBeat's FREE daily newsletter.


About Factor Therapeutics

Factor Therapeutics Limited operates as a biotechnology company that focuses on developing and commercializing advanced wound care therapies. The company was formerly known as Tissue Therapies Limited and changed its name to Factor Therapeutics Limited in May 2016. Factor Therapeutics Limited was incorporated in 2002 and is based in Brisbane, Australia.

Headlines

Anatara Lifesciences Limited (ANR.AX) Chair Transition
July 25, 2021 |  au.finance.yahoo.com
See More Headlines

Industry, Sector and Symbol

Industry
Biotechnology
Sub-Industry
N/A
Sector
Medical
CIK
N/A
Employees
N/A
Year Founded
N/A

Sales & Book Value

Annual Sales
$1,794.00
Book Value
A$0.03 per share

Profitability

Debt

Price-To-Earnings

Miscellaneous

Next Earnings Date
N/A
Optionable
Not Optionable

MarketRank

Overall MarketRank

0.93 out of 5 stars

Analyst Opinion: 0.0Community Rank: 4.7Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -












Factor Therapeutics (ASX:FTT) Frequently Asked Questions

What stocks does MarketBeat like better than Factor Therapeutics?

Wall Street analysts have given Factor Therapeutics a "N/A" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Factor Therapeutics wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

How were Factor Therapeutics' earnings last quarter?

Factor Therapeutics Limited (ASX:FTT) posted its quarterly earnings data on Thursday, August, 8th. The biotechnology company reported $0.00 EPS for the quarter.
View Factor Therapeutics' earnings history
.

Who are Factor Therapeutics' key executives?

Factor Therapeutics' management team includes the following people:
  • Ms. Melanie Farris M.A.I.C.D., ACIS) BComn, (AGIA, GradDip, ACG, Company Sec. & Non-Exec. Director

What is Factor Therapeutics' stock symbol?

Factor Therapeutics trades on the ASX under the ticker symbol "FTT."

How much money does Factor Therapeutics make?

Factor Therapeutics has a market capitalization of $0.00 and generates $1,794.00 in revenue each year.

What is Factor Therapeutics' official website?

The official website for Factor Therapeutics is factor-therapeutics.com.

Where are Factor Therapeutics' headquarters?

Factor Therapeutics is headquartered at L 19 179 Turbot St, BRISBANE, QLD 4000, Australia.

How can I contact Factor Therapeutics?

Factor Therapeutics' mailing address is L 19 179 Turbot St, BRISBANE, QLD 4000, Australia. The biotechnology company can be reached via phone at +61-7-33343900.


This page was last updated on 10/24/2021 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.